Fair Value Measurements (Narrative) (Detail) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 21, 2017	Dec. 21, 2016	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Nov. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized gain on interest rate swap			$ 2,051
Accrued contingent consideration			$ 703		$ 683
Number of shares to be issued			5,122	5,122
Aggregate principal amount of notes						$ 143,750
Theoretical borrowing rate used to calculate fair value of debt						6.50%
Fair value of the notes			$ 109,000
Fair value of future issuance of shares			90,400
Human Health Segment - Rising Reporting Unit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Recognized non-cash goodwill impairment charge, before tax					235,110
Foreign currency contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount			67,797
Unrealized gains (losses) on hedging activities			(331)	$ 295
Cash flow hedging | December 21, 2021 | Interest rate swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additional interest cost rate of derivative	2.005%
Derivative, notional amount	$ 100,000
Derivative, expiration date	Dec. 21, 2021
Notional balance of derivative			82,500
Citron and Lucid
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration			$ 703		$ 683
Number of shares to be issued		5,122		5,122